Immunome, Inc. (IMNM)

Immunome Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	582.69	653.48	143.35	98.68	20.32	49.23
Short-Term Investments	-	-	73.95	39.46	-	-
Cash & Short-Term Investments	582.69	653.48	217.3	138.14	20.32	49.23
Cash Growth	83.63%	200.72%	57.30%	579.73%	-58.72%	23.80%
Other Current Assets	11.62	7.3	4.04	6.56	2.33	7.41
Total Current Assets	594.31	660.78	221.34	144.7	22.65	56.64
Net Property, Plant & Equipment	19.91	17.61	14.39	3.64	0.97	0.86
Other Long-Term Assets	5.57	4.8	4.51	0.2	0.43	0.43
Total Assets	619.79	683.19	240.24	148.54	24.05	57.93
Accounts Payable	5.53	3.34	14.19	3.31	2.4	3.08
Accrued Expenses	21.88	41.65	33.18	8.03	4.93	6.65
Unearned Revenue	-	-	6.94	10.49	-	-
Total Current Liabilities	27.41	44.99	54.31	21.83	7.33	9.73
Long-Term Leases	3.69	3.86	4.77	1.34	-	-
Other Long-Term Liabilities	-	-	-	5.49	0.06	0.01
Total Long-Term Liabilities	3.69	3.86	4.77	6.83	0.06	0.01
Total Liabilities	31.11	48.85	59.08	28.66	7.39	9.74
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-in Capital	1,371	1,363	696.87	342.66	132.65	127.29
Accumulated Other Comprehensive Income	-	-	0.06	0.02	-	-
Retained Earnings	-782	-728.16	-515.77	-222.81	-116	-79.11
Shareholders' Equity	588.69	634.34	181.17	119.88	16.65	48.19
Total Liabilities & Equity	619.79	683.19	240.24	148.54	24.05	57.93
Total Debt	3.69	3.86	4.77	1.34	0	0
Net Cash (Debt)	579	649.63	212.53	136.8	20.32	49.23
Net Cash Growth	-10.87%	205.66%	55.36%	573.14%	-58.72%	25.76%
Net Cash Per Share	6.05	7.44	3.62	6.89	1.68	4.27
Book Value	588.69	634.34	181.17	119.88	16.65	48.19
Book Value Per Share	6.15	7.26	3.09	6.04	1.37	4.18
Tangible Book Value	588.69	634.34	181.17	119.88	16.65	48.19
Tangible Book Value Per Share	6.15	7.26	3.09	6.04	1.37	4.18

Updated May 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q